Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
about
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settingsAdding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
P2860
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@en
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@nl
type
label
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@en
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@nl
prefLabel
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@en
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@nl
P2093
P2860
P356
P1476
Hepatitis B e antigen predicts ...... B with lamivudine resistance.
@en
P2093
Akinobu Takaki
Fusao Ikeda
Haruhiko Kobashi
Junichi Kubota
Kazuhide Yamamoto
Kenji Miyoshi
Koichi Takaguchi
Nobuyuki Baba
Shin-Ichi Fujioka
Tetsuya Yasunaka
P2860
P304
P356
10.1002/JMV.23371
P577
2012-10-01T00:00:00Z